Semaglutide is a GLP-1 receptor agonist that supports weight loss by reducing appetite and caloric intake. This guide explains how it works, who may be eligible, typical dosing and titration, expected weight-loss timelines, side effects, contraindications (e.g., personal/family history of medullary thyroid carcinoma), and the importance of nutrition, physical activity, and behavioral support. It emphasizes that semaglutide must be prescribed and monitored by a licensed clinician and dispensed from regulated pharmacies.
How Semaglutide Works
Semaglutide mimics the hormone GLP-1, enhancing satiety and slowing gastric emptying, which helps reduce caloric intake. In clinical trials, many patients achieved clinically meaningful weight loss when combined with lifestyle measures.
Who Qualifies?
Eligibility typically includes adults with BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities (e.g., hypertension, dyslipidemia, type 2 diabetes), after lifestyle attempts. A clinician evaluates medical history, medications, and contraindications.
Dosing & Monitoring
Semaglutide dosing is titrated from low to target dose over weeks to improve tolerability. Regular follow-up assesses side effects (nausea, vomiting, constipation), adherence, and progress. Patients should be counseled on diet quality and physical activity.
Safety & Contraindications
Avoid use with personal/family history of medullary thyroid carcinoma or MEN2. Use caution in pancreatitis history. Report severe abdominal pain, persistent vomiting, dehydration, or signs of gallbladder disease.
References
- NICE. Obesity: identification, assessment and management.
- FDA Prescribing Information: Wegovy (semaglutide).
- Mayo Clinic: Semaglutide for weight management.